Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins the Nasdaq with a $126.4 million offering.